EGFR and non-small cell lung carcinoma: Furmonertinib (alflutinib, AST2818) is an irreversible EGFR TKI approved in China in 2021 to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with confirmed EGFR T790M mutations, whose disease has progressed during or after EGFR TKI therapy [16].